Can I Take Lion's Mane with Praluent (Alirocumab)?

What Is Alirocumab and How Does It Work?

Alirocumab is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9), preventing PCSK9 from degrading the LDL receptor on hepatocytes. With more LDL receptors available, the liver clears more LDL-C from the bloodstream. The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statins. [1]

Pharmacokinetic Profile Relevant to Supplement Interactions

Because alirocumab is a large-molecule biologic, it is not processed by the cytochrome P450 (CYP450) enzyme system that governs most small-molecule drug interactions. The FDA label states that alirocumab "is not expected to have pharmacokinetic drug interactions," since it is catabolized via proteolytic degradation pathways. [1] That single fact eliminates the most common mechanism by which herbs interfere with drugs.

Bioavailability after subcutaneous injection is approximately 85%, with peak serum concentrations reached at 3 to 7 days post-injection. Half-life ranges from 17 to 20 days. No CYP induction or inhibition from any co-administered substance will meaningfully change those parameters. [1]

Clinical Efficacy Context

The ODYSSEY LONG TERM trial (N=2,341) demonstrated that alirocumab 150 mg every two weeks reduced LDL-C by a mean of 61% from baseline versus placebo at 24 weeks (P<0.001). [2] Protecting that LDL reduction matters. Any supplement that might disrupt treatment adherence or introduce cardiovascular risk on its own should be evaluated carefully before you add it.

What Is Lion's Mane and Why Do People Take It?

Lion's mane (Hericium erinaceus) is a culinary and medicinal mushroom native to North America, Europe, and Asia. Supplement users most often cite cognitive support and peripheral nerve recovery as their reasons for taking it. Two groups of bioactive compounds drive most of the interest: hericenones (found in the fruiting body) and erinacines (found in the mycelium), both of which have been shown in cell and animal studies to stimulate nerve growth factor (NGF) synthesis. [3]

Cognitive and Neurological Evidence

A 2009 double-blind, placebo-controlled trial by Mori et al. (N=30) found that 1,000 mg of Hericium erinaceus fruiting-body powder three times daily for 16 weeks produced significantly higher scores on the Revised Hasegawa Dementia Scale versus placebo in older adults with mild cognitive impairment (P<0.001). [4] A 2023 pilot RCT (N=41) published in the Journal of Neurological Surgery reported improvements in subjective cognitive assessments after 28 days of 1.8 g/day of lion's mane extract. [5]

These trials involve small sample sizes. Effect sizes are encouraging but not definitive.

Cardiovascular and Lipid Effects

This is where Praluent users should pay closer attention. Animal data suggest Hericium erinaceus extracts may modestly reduce total cholesterol and triglycerides. [6] Whether that additive lipid effect is clinically meaningful alongside a PCSK9 inhibitor that already drops LDL-C by roughly 60% is unknown, and no human RCT has combined these two interventions.

Antiplatelet Activity

Preclinical data published in the International Journal of Medicinal Mushrooms identified polysaccharides in Hericium erinaceus that inhibit ADP-induced platelet aggregation in vitro. [7] That finding has not been replicated in a large human trial. Still, patients on anticoagulants (warfarin, apixaban, rivaroxaban) or dual antiplatelet therapy alongside their Praluent prescription should flag this possibility with their cardiologist.

Direct Interaction Analysis: Lion's Mane and Alirocumab

The core question is whether any biologically plausible mechanism exists for a harmful or beneficial interaction between these two agents. The analysis breaks into two categories.

Pharmacokinetic Interactions (Drug Metabolism)

No pharmacokinetic interaction is expected. Alirocumab does not rely on CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4, the enzymes most often inhibited or induced by botanical supplements. [1] Lion's mane does not carry a recognized CYP-inhibitor classification in the Natural Medicines database. A 2021 review in Nutrients examining the safety profile of Hericium erinaceus found no documented CYP450 interactions across all reviewed human case reports and trials. [8]

The verdict: pharmacokinetic interference is not a realistic concern.

Pharmacodynamic Interactions

Pharmacodynamic interactions occur when two agents act on the same physiological pathway, either amplifying or opposing each other's effects. Three plausible pathways are worth examining.

Lipid-lowering pathway. If lion's mane modestly lowers LDL-C or triglycerides (as suggested by animal data [6]), co-administration with alirocumab might produce additive LDL reduction. In practical terms, an already-low LDL-C (often <30 mg/dL on high-dose alirocumab plus statin) dropping further is not dangerous, but it warrants monitoring so your clinician can evaluate whether alirocumab dose adjustments are appropriate.

NGF stimulation and cardiovascular tissue. NGF has documented roles in cardiac sympathetic innervation and vascular smooth muscle. A 2020 review in Frontiers in Pharmacology noted that excessive NGF signaling in cardiac tissue could theoretically influence heart rate variability and atherosclerotic plaque stability, though this has not been demonstrated with oral lion's mane doses in humans. [9] This pathway remains theoretical at supplemental doses.

Antiplatelet pathway. As noted above, lion's mane may mildly inhibit platelet aggregation. [7] Alirocumab itself does not directly affect platelet function. The concern arises if a Praluent patient is also on aspirin, clopidogrel, or a direct oral anticoagulant. Triple additive antiplatelet or anticoagulant effects could theoretically increase bleeding risk, even if the lion's mane component is minor.

The table below summarizes the interaction framework a HealthRX clinician would apply when reviewing this combination.

| Interaction Type | Mechanism | Evidence Level | Clinical Significance | |---|---|---|---| | CYP450 pharmacokinetic | None expected | High (FDA label) | Not significant | | Additive LDL lowering | Possible cholesterol-lowering combination | Preclinical only | Monitor LDL-C | | NGF cardiovascular effects | Theoretical cardiac innervation pathway | In vitro / review only | Not significant at typical doses | | Antiplatelet additive effect | Platelet aggregation inhibition | Preclinical only | Low-moderate if on anticoagulants |

What the Guidelines Say About PCSK9 Inhibitors and Supplements

The 2018 AHA/ACC Cholesterol Guideline (Grundy et al.) does not specifically address lion's mane but does state that "dietary supplements and herbal products are not recommended as a substitute for, or in addition to, evidence-based lipid-lowering therapies unless evaluated in clinical trials." [10] That language does not prohibit supplements alongside PCSK9 inhibitors. It asks clinicians to evaluate each case.

The American College of Cardiology's 2022 Expert Consensus Decision Pathway on PCSK9 inhibitor use emphasizes adherence as the dominant variable in long-term outcomes. [11] Any supplement that a patient believes is helping cognition and that has low toxicity may actually support adherence by increasing overall health engagement, provided the supplement does not introduce harm.

Dr. Jennifer Robinson, co-chair of the ODYSSEY OUTCOMES trial, stated in a 2018 editorial in JAMA Cardiology: "The magnitude of cardiovascular event reduction with PCSK9 inhibition correlates directly with absolute LDL-C lowering," underscoring why protecting treatment efficacy matters. [12]

Safety Profile of Lion's Mane: What the Evidence Shows

Lion's mane carries a favorable safety record in published trials. The Mori 2009 trial (N=30) reported no serious adverse events over 16 weeks at 3,000 mg/day. [4] A 2023 systematic review in Phytotherapy Research identified mild gastrointestinal symptoms (nausea, abdominal discomfort) in fewer than 5% of participants across pooled data. [13]

Allergic Reactions

Rare cases of contact dermatitis and respiratory allergy have been reported in mushroom-farm workers. Oral supplementation hypersensitivity is uncommon but documented. Patients with mushroom allergies should avoid lion's mane or consult an allergist first.

Drug Interactions Documented in Literature

The 2021 Nutrients review found no drug interactions documented in human clinical trials between lion's mane and any prescription cardiovascular medication. [8] Case reports of antiplatelet potentiation with anticoagulants remain isolated and low-quality.

Pregnancy and Lactation

No adequate human safety data exist for lion's mane during pregnancy or lactation. Women who are pregnant and taking Praluent (a category not formally studied in large RCTs) should avoid lion's mane until data are available.

Practical Guidance: Taking Lion's Mane While on Praluent

The following steps reflect best practice for a patient who wants to add lion's mane to an existing alirocumab regimen.

Step 1: Disclose Before You Start

Tell your cardiologist or prescribing clinician before adding any supplement. This is non-negotiable for patients on PCSK9 inhibitors, given the cardiovascular stakes. A brief telehealth message takes under two minutes.

Step 2: Identify Your Full Medication List

If you also take aspirin, clopidogrel, warfarin, apixaban, rivaroxaban, or edoxaban, the mild antiplatelet activity of lion's mane becomes a higher priority concern. Your clinician may want a baseline platelet function panel before you begin.

Step 3: Choose a Standardized Extract

Supplement quality varies widely. Look for products standardized to hericenone and erinacine content and tested by a third-party lab (NSF International, USP, or ConsumerLab). The doses used in clinical trials range from 500 mg to 3,000 mg of dried fruiting body extract per day. [4]

Step 4: No Dose-Separation Window Is Required

Because alirocumab is not absorbed orally and is not metabolized via CYP450, there is no pharmacokinetic rationale for separating alirocumab injections from lion's mane doses by time. Take both according to your normal schedule.

Step 5: Monitor LDL-C at Your Next Scheduled Draw

Your cardiologist likely orders a lipid panel every 4 to 12 weeks when initiating or adjusting PCSK9 inhibitor therapy per ACC guidance. [11] Note your lion's mane start date and review your next LDL-C result in that context.

Step 6: Watch for Bleeding Signs

Easy bruising, prolonged bleeding from cuts, or unusual nosebleeds should prompt you to stop lion's mane and contact your prescriber. This is especially true if you are on concurrent anticoagulation.

Special Populations

Patients with Familial Hypercholesterolemia

Familial hypercholesterolemia (FH) affects approximately 1 in 250 people globally, according to the FH Foundation and published prevalence data from the European Heart Journal. [14] PCSK9 inhibitors are often the only agents capable of reaching LDL-C goals in heterozygous FH. Any supplement that might compromise adherence or raise any cardiovascular risk, however small, deserves extra scrutiny in this population.

Elderly Patients

Older adults take lion's mane most often for cognitive concerns. Older patients are also more likely to have ASCVD and to be on Praluent. Renal or hepatic impairment does not alter alirocumab pharmacokinetics (the FDA label confirms no dose adjustment needed for either), and lion's mane has not shown accumulation-related toxicity in older adults in the reviewed trials. [1][4] The antiplatelet caution applies with equal force, however, because older patients fall at higher rates and bleed more severely when antiplatelet activity is elevated.

Patients Also on Statins

Most alirocumab patients are co-prescribed a statin such as rosuvastatin or atorvastatin. Statins are metabolized primarily via CYP3A4 (atorvastatin) or minimally via CYP2C9 (rosuvastatin). Lion's mane does not significantly inhibit these enzymes based on available data. [8] No dose adjustment is warranted for the statin component.

What to Do If You Are Already Taking Both

Some patients begin lion's mane for cognitive reasons before asking about interactions. If you are already taking lion's mane alongside alirocumab and have not had problems, the evidence suggests you are unlikely to be harmed by the combination at standard doses. Still, take these steps.

First, report the combination to your prescribing clinician at your next visit or via a patient portal message. Second, review your most recent LDL-C result. If LDL-C has drifted upward since you added lion's mane, that change is almost certainly due to adherence or diet, not a direct supplement-drug interaction, but it is worth discussing. Third, if you are on any anticoagulant, request a review of your bleeding risk profile.

No evidence supports stopping lion's mane abruptly because of a Praluent prescription alone. The decision to continue or discontinue should be individualized.